Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study.
The objective of this study was to investigate the efficacy of pirenzepine in the treatment of clozapine-induced hypersalivation. Pirenzepine is reported to counteract hypersalivation by its selective antagonistic activity on the M4-muscarinic receptor, which is stimulated by clozapine. Twenty patients with clozapine-induced hypersalivation underwent a random-order, double-blind, placebo-controlled, cross-over trial which lasted 8 weeks each for the pirenzepine and placebo investigations, with a 4-week washout period in between. The severity of hypersalivation was assessed using an objective measure: saliva production monitored through the diameter of wetted surface on tissue paper placed over the patient's pillow. Our study showed that pirenzepine had no significant therapeutic effect on hypersalivation compared with placebo, suggesting that hypersalivation induced by clozapine might have a neurobiological basis other than the M4-muscarinic receptor.
Bai
Y M
YM
Department of Psychiatry, Yu-Li Veterans Hospital, Hua-Lien, Taiwan.
Lin
C C
CC
Chen
J Y
JY
Liu
W C
WC
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects; D003024:Clozapine / Q000009:adverse effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D010890:Pirenzepine / Q000627:therapeutic use*; D012798:Sialorrhea / Q000139:chemically induced* / Q000188:drug therapy*
D014150:Antipsychotic Agents; D018727:Muscarinic Antagonists; D010890:Pirenzepine; D003024:Clozapine